A trial to find out how well CVHNLC works at different dose levels and how safe it is in combination with pembrolizumab in patients with lung cancer that cannot be completely cured.

2024-519651-28-00 Protocol CV-HNLC-001 Human pharmacology (Phase I) - First administration to humans Ended

End 11 May 2026 · Status Ended · 2 EU/EEA countries · 12 sites · Protocol CV-HNLC-001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 33
Countries 2
Sites 12

metastatic squamous non-small cell lung cancer

Key facts

Sponsor
CureVac SE
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Respiratory Tract Diseases [C08], Diseases [C] - Neoplasms [C04]
Trial duration
completed 11 May 2026
Decision date (initial)
2025-06-04
Transition trial
No
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

metastatic squamous non-small cell lung cancer

VersionLevelCodeTermSystem organ class
24.0 LLT 10085300 Squamous non-small cell lung cancer 100000004848

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

CureVac SE

Sponsor organisation
CureVac SE
Address
Leipziger Strasse 35, Bierstadt Bierstadt
City
Wiesbaden
Postcode
65191
Country
Germany

Scientific contact point

Organisation
CureVac SE
Contact name
Julia Bosch

Public contact point

Organisation
CureVac SE
Contact name
Julia Bosch

Locations

2 EU/EEA countries · 12 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ended 18 7
Spain Ended 12 5
Rest of world
United States
3

Investigational sites

France

7 sites · Ended
Institut Bergonie
n/a, 180 R De Saint Genes, 229 Cours De L Argonne, Bordeaux
Centre Hospitalier Regional De Marseille
n/a, 264 Rue Saint Pierre, 13005, Marseille
Centre Hospitalier Universitaire De Rennes
Service de pneumologie Pneumology department, 2 Rue Henri Le Guilloux, 35000, Rennes
Institut Gustave Roussy
n/a, 114 Rue Edouard Vaillant, 94800, Villejuif
Institut Curie
Oncologie Médicale, 26 Rue D Ulm, 75005, Paris
Oncopole Claudius Regaud
Medical Oncology, 1 Avenue Irene Joliot Curie, 31100, Toulouse
Institut De Cancerologie De L Ouest
Medical oncology, Boulevard Jacques Monod, 44805, Saint-Herblain Cedex

Spain

5 sites · Ended
Hospital Universitario Virgen De La Victoria
Oncología Médica, Campus De Teatinos Sn, Puerto De La Torre, Malaga
Hospital Universitari Vall D Hebron
Oncología, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Hospital Quironsalud Barcelona
NEXT Oncology Barcelona, Placa D'alfonso Comin 5-7, 08023, Barcelona
Hospital Universitario Fundacion Jimenez Diaz
Oncología, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Hospital Universitario Hm Sanchinarro
Oncología, Unidad de Fase I START Madrid-CIOCC, Calle Ona 10, 28050, Madrid

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-02-17 France Acceptable
2025-05-28
2025-06-03